title: Cost Effectiveness of Cetuximab in 1st-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer in Scotland: A Summary of the Submission to the Scottish Medicines Consortium.
authors.affiliation: MAPI, London, UK.
authors.forename: J
authors.initials: J
authors.lastname: Jarrett
authors.affiliation: MAPI, London, UK.
authors.forename: O
authors.initials: O
authors.lastname: Ovcinnikova
authors.affiliation: Merck Serono Ltd., UK, UK.
authors.forename: A
authors.initials: A
authors.lastname: Hnoosh
authors.affiliation: Merck Serono Ltd., UK, UK.
authors.forename: G
authors.initials: G
authors.lastname: Harty
authors.affiliation: Merck Serono Ltd., FELTHAM, UK.
authors.forename: B
authors.initials: B
authors.lastname: Byrne
authors.affiliation: Merck Serono, Darmstadt, Germany.
authors.forename: P
authors.initials: P
authors.lastname: von Hohnhorst